Contineum Therapeutics, Inc. CTNM
- JNJ-89495120 — Major Depressive Disorder Phase 2
- JNJ-89495120 — Relapsing-Remitting Multiple Sclerosis Phase 2
M1R (1 companies · 2 programs)
Companies with an active program directed at M1R.
Companies with an active program directed at M1R.